Showing 719 results
-
Media Release /- 2018 STEP Program™ designed to support unique proposals from nonprofit organizations that serve people living with sickle cell disease- Novartis will select proposals that demonstrate innovation in…
-
Media Release /
-
Media Release /Entresto® (sacubitril/valsartan) outperformed commonly used heart failure medicine enalapril in landmark study; delivered significantly greater and more rapid reductions in an established biomarker…
-
Media Release /
-
Media Release /- Additional analysis from pivotal Phase III SOLAR-1 clinical trial studying investigational alpha-specific PI3K inhibitor BYL719 (alpelisib) and fulvestrant in patients with PIK3CA-mutated HR+/HER2…
-
Media Release /
-
Media Release /-- Kymriah was the first CAR-T cell therapy to ever be approved by a regulatory authority-- Since 1970, more than 40 Novartis innovative therapies have been recognized by the Prix Galien Foundation…
-
Media Release /
-
Media Release /- Year two results consistent with previously announced key secondary endpoint data on retinal fluid (IRF and/or SRF) showing superior reductions versus aflibercept- Superior reductions in central…
-
Media Release /
